266.18MMarket Cap-7571P/E (TTM)
1.640High1.580Low427.64KVolume1.600Open1.580Pre Close686.65KTurnover0.33%Turnover RatioLossP/E (Static)167.41MShares2.85052wk High1.20P/B203.89MFloat Cap1.02552wk Low--Dividend TTM128.23MShs Float22.910Historical High--Div YieldTTM3.80%Amplitude1.025Historical Low1.605Avg Price1Lot Size
ATAI Life Sciences Stock Forum
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
You should check out $ATAI Life Sciences(ATAI.US)$ as well. 😉
$ATAI Life Sciences(ATAI.US)$ looks good too! It'll be interesting to see the advancements coming with their medicine. Especially with John Hopkins University doing similar research.
$ATAI Life Sciences(ATAI.US)$ looks good too! It'll be interesting to see the advancements coming with their medicine. Especially with John Hopkins University doing similar research.
$ATAI Life Sciences(ATAI.US)$ looks pretty good too!
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
• ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hour...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...
No comment yet